Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a Chinese pharmaceutical company, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for a suite of drugs including HRS-2189, HRS-5041, HRS-1358, HRS-8080, SHR-8068, adebrelimab, and HRS-6209. The company is set to initiate an open, multi-center Phase Ib/II clinical study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of HRS-2189 in combination with various treatments for advanced unresectable or metastatic solid tumors.
Study Design and Combination Therapies
The study will evaluate HRS-2189 in combination with Fulvestrant, with or without HRS-6209, or in combination with HRS-6209 with or without HRS-8080, or with HRS-6209 with or without HRS-1358, or with abiraterone with or without prednisone, or in combination with HRS-5041, or with adebrelimab with or without SHR-8068 with or without chemotherapy, or with abiraterone plus bevacizumab. This comprehensive approach aims to explore the potential synergistic effects of these combinations in treating solid tumors.
Drug Profiles
HRS-2189 is a drug that regulates the expression of multiple oncogenes and is intended for the treatment of advanced malignant tumors. HRS-5041 is an androgen receptor-targeted PROTAC small molecule under development for prostate cancer. HRS-1358 is an estrogen receptor (ER)-targeted PROTAC molecule. HRS-8080 is an oral selective estrogen receptor degrader (SERD) being developed for ER positive and ER mutant breast cancer. Adebrelimab is a PD-L1 monoclonal antibody (mAb) approved in China for the treatment of first-line extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy. SHR-8068 is an in-licensed CTLA-4 mAb. HRS-6209 is a novel CDK4 inhibitor designed for the treatment of malignant tumors.-Fineline Info & Tech
Leave a Reply